ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

ABDELBASET YOUSSEF MD

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,713Medicare Part D Prescriptions Filled, Including Refills

Rank: 49 out of 2035

$603K Total Retail Price of All Prescriptions

Rank: 190 out of 2035

429 Patients Receiving at Least One Drug in Part D
18%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

80% of this provider’s 429 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

10% of this provider’s 3,151 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

37 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
HYDROCODONE-ACETAMINOPHEN 2,627 545 S3 1 2
CARISOPRODOL 2,130 276 R 10 2 57
TRAMADOL HCL 854 147 3 19
OMEPRAZOLE 464 82 4 5
AZITHROMYCIN 429 94 5 39
IBUPROFEN 353 42 6 43
SULFAMETHOXAZOLE-TRIMETHOPRIM 315 32 7 110
LISINOPRIL 300 102 8 3
AMLODIPINE BESYLATE 288 78 9 6
PROAIR HFA 280 73 10 31
POTASSIUM CHLORIDE 259 78 11 18
SIMVASTATIN 231 60 12 1
LISINOPRIL-HYDROCHLOROTHIAZIDE 218 50 13 26
FUROSEMIDE 214 78 14 7
AMOXICILLIN 213 47 15 116
CIPROFLOXACIN HCL 212 40 16 63
GABAPENTIN 211 23 17 14
CLONIDINE HCL 181 36 18 61
METOPROLOL TARTRATE 162 60 19 8
VENTOLIN HFA 152 11 20 80
LIDOCAINE-PRILOCAINE 140 32 21 326
OXAPROZIN 138 37 10 22 375
METFORMIN HCL 129 16 23 9
SPIRIVA 123 39 24 44
NEXIUM 122 52 25 51
HYDROCHLOROTHIAZIDE 119 16 26 12
TAMSULOSIN HCL 118 53 27 25
ADVAIR DISKUS 117 35 28 38
RANITIDINE HCL 112 22 29 28
ZOLPIDEM TARTRATE 108 16 30 21
PREDNISONE 101 15 31 36
ATORVASTATIN CALCIUM 99 33 32 13
AMOX TR-POTASSIUM CLAVULANATE 97 0 33 168
PROMETHAZINE HCL 91 0 R 34 106
ATENOLOL 86 11 35 10
CLOTRIMAZOLE 79 11 36 331
VOLTAREN 76 12 37 141
CEPHALEXIN 75 21 38 91
FLUTICASONE PROPIONATE 74 11 39 29
LEVOTHYROXINE SODIUM 73 0 40 4
GLYBURIDE 72 30 R 41 74
CYMBALTA 67 0 42 59
TRAZODONE HCL 66 0 43 50
LYRICA 65 0 44 89
CELEBREX 64 11 45 104
NAPROXEN 62 0 46 92
KETOCONAZOLE 62 17 46 215
CRESTOR 62 11 46 41
MUPIROCIN 59 13 49 275
LIDODERM 57 0 50 72
ALENDRONATE SODIUM 57 0 50 27
QUETIAPINE FUMARATE 56 0 52 70
FLUCONAZOLE 54 0 53 198
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 30, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.